Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start.

Purpose: This study reports the safety and efficacy of OncofidP-B, a novel compound under development by Fidia Farmaceutici S.p.A.

[Management of prostate cancer biochemical recurrence in the clinical guidelines].

Objective: Review of the Guidelines which have major impact on the urological field, in order to compare and to know their recommendations in the diagnosis and management of biochemical relapse after a healing treatment of prostate cancer (radical prostatectomy or radiotherapy).

Methods: We review the Guidelines of the European Urological Association (EAU), the American Urological Association (AUA), of the National Comprehensive Cancer Network (NCCN) and those of the National Institute for Health and Clinical Excellence (NICE), as well as the scientific evidence on which they are based.

Results: In this paper we state the complexity of the subject being dealt with and coincidences and differences among them.

Cadaver donor kidney retransplantation in the pediatric patient: complications and long-term outcome.

Purpose: We compared the outcome of second and third kidney allografts with that of the first kidney allograft in pediatric recipients.

Materials And Methods: We classified 173 cadaveric kidney recipients into 2 groups. Group 1 comprised 120 first transplants and group 2 comprised 53 retransplants, including 43 second and 10 third transplants.

[Results of the use of donors under 3 years of age for pediatric renal transplantation].

Objectives: To evaluate the functional results and incidence of complications in a series of pediatric renal transplants using grafts from pediatric donors under 3 years of age.

Methods: We review a serious of 19 renal transplants consecutively performed in pediatric receptors with donors under the age of 3 years. We analyze immediate function, medical and surgical complications, and long and mid-term graft and patient survivals.